This is the authors' abstract. We don't add key points for this paper.
Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Badran et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: